Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting now · Phase 3

Conditions studied: Stage II Colorectal Cancer, Stage III Colorectal Cancer

In brief

For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.

Key facts

Study ID

NCT05086614

Run by

Fudan University

People needed

2500

Starts

2021-04-01

Expected to finish

2027-03-31

Last updated by the study team

2021-10-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Colorectal cancer receiving radical resection
• Pathologically diagnosed with high-risk stage II or stage III
• Eastern Cooperative Oncology Group performance status of 0-2
• Adequate hepatic, renal, and hematologic function

You may not qualify if…

• Had previously taken any immune-promoting drugs
• Pregnancy or lactation

Where it is running

• Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.